August 22, 2024 9:08am

Seasonality prognostication aren’t accurate and I am feelin’ “NOTHING” today

Today’s highlight, “job gains in July, which also saw the unemployment rate rise to a post-pandemic high of 4.3%.”

A daily analytic read-out from RMi is constructed of signals thought-provoking share pricing situations

Never leave an investor uninformed

Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.

My interpretation of the morning’s numbers is written to be informative; it’s built on what happened or will happen behind the headline today!

 

Thursday: The pre-open Dow futures are UP +0.04% or (+12 points), the S&P futures are UP +0.15% or (+8) and the Nasdaq futures are UP +0.25% or (+49 points)

  • Stock futures ticked barely … higher Thursday,
  • European stocks moved higher
  • Asia markets mostly rise

 

Henry’omics:

We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies …

Wednesday: The Dow closed UP +55.52 points or +0.14%, the S&P closed UP +23.73 points or +0.42% while the Nasdaq closed UP +102.05 points or +0.57%

  • Wednesday’s advance/decline line ended with a positive close of 29 incliner, 3 decliners and 3 flats

Economic Data Docket: The number of Americans applying for unemployment benefits rose modestly last week, but remains at healthy levels.

  • Initial claims for state unemployment benefits rose 4,000 to a seasonally adjusted 232,000 for the week ended Aug. 17, the Labor Department said on Thursday.
  • Economists had forecast 230,000 claims for the latest week.

 

Thursday’s RegMed Investors (RMi) Closing bell: cell and gene therapy enjoyed the closing dinner. After “uncle algo and his electronic trading dwarfs” popped-in for a big dinner of share pricing.” … https://www.regmedinvestors.com/articles/13584

 

Q3/24:

  • August – I neutral, 6 positive and 8 negative closes
  • July: 1 market holiday. 1 day off, 6 negative, 1 neutral and 12 positive closes

 

Companies in my headlights – It’s your decision; I provide ideas and context:

I post about “indication intelligence” devoting my time to collection and analysis of information to assist investors with insight into sector vulnerabilities and strengths. A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

  • Yet again, I am passing on forecasting the daily indications as JOBS expectations are in focus as expectation in the aftermarket fluctuated while the pre-open waits for the all-clear alarm …  it is still a mix of ups, downs and just unknowns.

 

The BOTTOM LINE:  My advice: keep opening that portfolio envelope and think a game of monopoly and follow RMi’s interchanges to gain profit moves or recoup losses – eat the popcorn and ponder ANY moves.

Short on words, long on being Judicious!

 

If I have learned one thing as a former research analyst in a venture and public fund, operating executive, x-FBI, x-military officer, x-corporate manager and officer, an adjunct business school (MBA) professor now a journalist; my life and your portfolio are largely tied to knowledge of price movements and questioning pricing targets and just about … everything.

As a quantamental “plotter” I equate myself to a quantitative analyst straddling fundamental stock picking to produce better results for investors. the term “quantamental,” blends the two styles setting forth my difference retail, trading and multiple investor categories.

TRUST but, VERIFY!

 

Watch the “numbers, charts and indicators” measure the daily, weekly, and monthly charts to filter out or lessen the noise of back-and-forth share pricing from the sector rotation.

  • The short-term moving averages help you identify the momentum of the trend — that is, overbought or oversold

 

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”
  • The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.
  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.